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Abstract
Previous studies have shown that systemic, but not unilateral intra-prefrontal cortex administration of
non-competitive NMDA antagonists, increased prefrontal activity, the cortical eﬄux of serotonin, and
induced stereotypies. In this work we used in-vivo microdialysis and immunohistochemistry to test the
hypothesis as to whether MK-801 and ketamine need to act on both prefrontal cortices to reproduce these
neurochemical and behavioural changes. Dialysis probes were implanted in the medial prefrontal cortex,
and extracellular serotonin as well as behavioural stereotypies was measured after systemic adminis-
tration of MK-801 and ketamine (1 mg/kg and 25 mg/kg, respectively), and unilateral and bilateral
perfusion of both drugs (300 mM and 3 mM, respectively). Additionally, the prefrontal (glutamatergic) level
of activity was measured using c-Fos immunohistochemistry. Systemic and bilateral (but not unilateral)
prefrontal administration of MK-801 and ketamine increased serotonin eﬄux whereas only systemic
administration of both drugs produced hyperlocomotion and stereotypies. The unilateral perfusion of
1 mM tetrodotoxin in the medial prefrontal cortex reduced increases of serotonin in both hemispheres,
the expression of c-Fos in the contralateral side, and stereotypy scores after systemic NMDA antagonists.
Our results support the hypothesis that a bilateral impairment of cortical inhibition in the medial
prefrontal cortex is needed for non-competitive NMDA antagonists to induce the state of pyramidal
cell hyperactivity and concurrent eﬄux of serotonin. Furthermore, hyperlocomotion and stereotypies
produced by MK-801 and ketamine do not appear to result from changes in the activity of prefrontal
cortex although this structure exerts some control over these behaviours.
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Introduction
The hypothesis of N-methyl-D-aspartate (NMDA)
receptor hypofunction in schizophrenia stems from
the observation that NMDA antagonists, such as
phencyclidine (PCP) and ketamine, induce psychotic,
negative and cognitive symptoms, that resemble those
present in schizophrenia (Javitt & Zukin, 1991; Krystal
et al. 1994). Furthermore, several functions that are
impaired in schizophrenia (e.g. working memory) are
dependent on the integrity of the prefrontal cortex
(PFC) (Goldman-Rakic, 1994). In rats, systemic ad-
ministration of NMDA antagonists induces hyper-
locomotion and stereotypies (Homayoun et al. 2004),
behaviours that are commonly associated with
positive symptoms of schizophrenia (Lipska &
Weinberger, 2003 ; Sams-Dodd, 1997), and are thought
to result from elevated dopaminergic and serotonergic
tones (Giros et al. 1996; Jentsch et al. 1998). Accord-
ingly, NMDA receptor blockade increases glutamate
and serotonin (5-HT) release in the medial prefrontal
cortex (mPFC) of rats (Adams & Moghaddam, 2001;
Lo´pez-Gil et al. 2007). These eﬀects occur in parallel
with an enhanced prefrontal activity measured as
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increased ﬁring rate of pyramidal neurons (Jackson
et al. 2004; Kargieman et al. 2007; Suzuki et al. 2002) and
expression of c-fos (Kargieman et al. 2007; Va¨isa¨nen
et al. 2004; Zuo et al. 2009).
A highly active serotonergic transmission has been
implicated in schizophrenia (Meltzer, 1989) and in the
hyperlocomotion induced by the ablation of the NR2A
subunit of NMDA receptors (Miyamoto et al. 2001). On
the other hand, locomotion and stereotypy induced
by 3,4-methylenedioxymethamphetamine (MDMA) is
strongly correlated with prefrontal release of 5-HT
(Baumann et al. 2008). However, the precise role of
cortical 5-HT on similar eﬀects produced by NMDA
antagonists remains to be determined. In a previous
work we put forward the idea that an excessive
serotonergic eﬄux in the mPFC can be potentially
indicative of negative/cognitive symptomatology of
schizophrenia, which is better treated with atypical
antipsychotic drugs (Lo´pez-Gil et al. 2007). Further-
more, 5-HT eﬄux in the mPFC is dependent of the
in-vivo excitatory (glutamatergic) transmission in this
structure. This is based on two main observations :
(1) the stimulation of mPFC output enhances 5-HT
eﬄux in the dorsal raphe nucleus (DR) (Amargo´s-
Bosch et al. 2003; Celada et al. 2001), which is sugges-
tive of 5-HT cell activation in this structure (Tao
& Auerbach, 2000) that would lead to increased
5-HT eﬄux in the mPFC; and (2) the increased 5-HT
eﬄux elicited by MK-801 is strongly dependent
on the stimulation of a-amino-3-hydroxy-5-methyl-4-
isoxazole-4-propionic acid (AMPA) receptors in the
mPFC, inasmuch as intra-mPFC perfusion of NBQX
(an AMPA receptor antagonist) prevented an increase
in 5-HT (and glutamate) levels after systemic MK-801
administration (Lo´pez-Gil et al. 2007). In previous
studies using extracellular recordings and micro-
dialysis, unilateral intra-mPFC perfusion of non-
competitive NMDA antagonists failed to replicate the
eﬀects of their systemic administration (Aghajanian &
Marek, 2000 ; Lo´pez-Gil et al. 2007; Lorrain et al. 2003;
Suzuki et al. 2002), which would suggest an extra-
cortical site(s) of action. In contrast, recent data have
suggested that these agents preferentially inhibited
prefrontal GABAergic interneurons, thus creating a
disinhibited state of pyramidal activity, which is as-
sociated with excessive neuronal activity (Homayoun
& Moghaddam, 2007) and increased eﬄux of gluta-
mate and 5-HT within mPFC (Adams & Moghaddam,
2001; Lo´pez-Gil et al. 2007). To reconcile such contra-
dictory data, the present work was aimed at examin-
ing whether non-competitive NMDA antagonists
would need to block NMDA receptors located on
GABAergic neurons of mPFC to produce the changes
in prefrontal serotonergic transmission (5-HT eﬄux),
pyramidal activity (c-Fos expression in vesicular
glutamate transporter-1 (vGluT1)-containing cells) and
stereotypies observed after systemic administration.
To this end, a microdialysis probe was implanted in
each mPFC and extracellular 5-HT and stereotypies
were examined after systemic, unilateral and bilateral
intra-mPFC administration of MK-801.
Materials and methods
Animals and treatments
Male Wistar rats (Charles River Laboratories, Spain)
weighing 250–280 g were used. Food and water were
available ad libitum. All experimental procedures
followed European Union regulations (Oﬃcial Journal
of the European Communities L358/1, 18 December
1986), and were approved by the Institutional Animal
Care and Use Committees. Dizocilpine maleate
(MK-801, Sigma-Aldrich, Spain) and ketamine hydro-
chloride (Tocris Bioscience, UK) were dissolved
in saline for intraperitoneal (i.p.) or subcutaneous
(s.c.) administration, respectively, or in artiﬁcial
cerebrospinal ﬂuid (aCSF) for intra-mPFC perfusion.
Tetrodotoxin (TTX, Sigma-Aldrich) was dissolved in
aCSF. Doses and perfused concentrations of MK-801
and ketamine were selected from previous studies
(Lo´pez-Gil et al. 2007; Moghaddam et al. 1997), taking
into consideration their diﬀerent aﬃnity for the
NMDA channel site (Murray et al. 2000).
Microdialysis procedures
Concentric dialysis probes with a 4-mm membrane
were implanted bilaterally under sodium pento-
barbital anaesthesia (60 mg/kg i.p.) in the mPFC
(AP+3.2 mm, L¡0.6 mm, DVx6.0 mm from bregma)
according to Paxinos & Watson (1986). Microdialysis
experiments were conducted 20–24 h after surgery
in freely moving rats by continuously perfusing
probes with aCSF (125 mM NaCl, 2.5 mM KCl, 1.26 mM
CaCl2, 1.18 mM MgCl2, 1 mM citalopram) at a rate of
1.5 ml/min. The addition of an uptake inhibitor to
the perfusion ﬂuid was used to decrease clearance
from the extracellular space and magnify the release
component of extracellular 5-HT (Adell et al. 2002).
This did not interfere with the local or systemic actions
of the drugs used in the present experiments (Lo´pez-
Gil et al. 2007). Dialysate samples of 30 ml were col-
lected every 20 min, and 5-HT was determined by
HPLC as described previously (Lo´pez-Gil et al. 2007).
Brieﬂy, the HPLC system consisted of a Waters
717plus autosampler (Waters Cromatograﬁa, Spain),
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a Hewlett-Packard series 1050 pump (Agilent Tech-
nologies, Spain), an octadecyl silica (ODS) column
(7.5 cmr0.46 cm; Beckman, USA), and an ampero-
metric detector Hewlett-Packard 1049 (Agilent Tech-
nologies) set at an oxidation potential of 0.6 V. The
mobile phase consisted of 0.15 M NaH2PO4, 1.8 mM
octyl sodium sulfate, 0.2 mM EDTA (pH 2.8, adjusted
with phosphoric acid), and 30% methanol and was
pumped at 0.7 ml/min. At the completion of dialysis
experiments, rats were given an overdose of sodium
pentobarbital and a Fast Green solution was perfused
through the dialysis probes to stain the surrounding
tissue.
c-Fos and vGluT1 immunostaining
In order to mimic microdialysis setting, a group of
rats were implanted unilaterally with one probe, and
systemic MK-801 was administered i.p. 20–24 h later.
c-Fos expression is considered to be a marker of
neuronal activity (Dragunow & Faull, 1989) and was
measured in the contralateral side to avoid the im-
plantation site in the ipsilateral side. Immuno-
histochemistry protocol was as described previously
(Zuo et al. 2009). Brieﬂy, 2 h after administration of
MK-801 (1 mg/kg), rats were deeply anaesthetized
with sodium pentobarbital (60 mg/kg) and then per-
fused transcardially with cold 0.9% NaCl followed by
10% buﬀered formalin (Sigma-Aldrich). Each brain
was removed immediately, post-ﬁxed in the same
ﬁxative for 24 h at 4 xC, and then cut on a vibratome in
the coronal plane at 30 mm. Three consecutive sections
of the mPFC and DR for each rat were collected free
ﬂoating. Sections were incubated for 25 min at room
temperature (RT) in 3% H2O2 to inactivate endogen-
ous peroxidase. Thereafter, sections were washed
twice in 0.01 M PBS containing 0.2% Triton X-100.
After blocking with 5% BSA for 1 h at RT, sections
were incubated overnight at 4 xC with rabbit poly-
clonal antiserum raised against c-Fos (sc-50, Santa
Cruz Biotechnology, USA) diluted 1:500 in PBS con-
taining 0.2% Triton X-100, 0.2% gelatin and 5% BSA.
Following incubation in the primary antibody,
sections were washed three times in PBS containing
0.2% Triton X-100 and incubated with biotinylated
goat anti-rabbit immunoglobulin G (IgG) antiserum
(1:200, Vector Laboratories, USA), for 1 h at RT.
Sections were then washed with PBS containing 0.2%
Triton X-100, incubated for 1 h with avidin-biotin
peroxidase complex (1 :1000 ; Vectastain ABC kit,
Vector Laboratories), washed in 0.01 M PBS, and
ﬁnally revealed with diaminobenzidine for 10–15 min.
Sections were then slide-mounted onto gelatin-coated
slides. The number of c-Fos-positive cells in mPFC and
DR were measured in triplicate. The procedure also
included negative controls with omission of the pri-
mary antibody, which did not show any immuno-
reaction (data not shown). c-Fos-positive nuclei were
counted relative to a threshold based on staining
density, which was established by visual observation
blinded to treatment. Although the threshold is a
subjective measure, the stereological cell counting
provided a sensible improvement of the method
accuracy.
In order to examine whether mPFC cells immuno-
reactive for c-Fos after MK-801 administration were
pyramidal neurons, a double immunohistochemistry
procedure was performed combining c-Fos and
vGluT1 immunostaining, the latter being a speciﬁc
marker of glutamatergic (pyramidal) neurons (Fremeau
et al. 2001; Omelchenko & Sesack, 2007). Brieﬂy,
after a ﬁrst immunostaining with c-Fos as described,
a second procedure was carried out under the same
conditions, but using guinea-pig polyclonal antiserum
raised against vGluT1 (Millipore, USA) diluted
1:2000, a biotinylated goat anti-guinea-pig IgG anti-
serum (1 :200, Millipore), and vector VIP (Vector
Laboratories) as chromogen. As described previously
(Fremeau et al. 2001), vGluT1 is distributed periph-
erally in cortical pyramidal neurons, just underneath
the plasma membrane, thus leaving a clear zone that
corresponds to the cytoplasm (Fig. 5b).
Brain sections were examined in an Olympus BX51
Stereo Microscope (Japan). Stereological cell counting
was performed using Visiopharm Integrator System
software for stereological analysis (Visiopharm A/S,
Denmark).
Behavioural measures
Gross behavioural scores were assessed by direct
observation of rats undergoing in-vivo microdialysis
and were based on a method described previously
(Jackson et al. 2004). Stereotypies were rated during
the last 5 min of each 20-min sample. Animals re-
ceived a score of 0 (absence), 1 (presence) or 2 (intense ;
>50% of the 5-min block) for each of the following
motor stereotypies commonly associated with NMDA
antagonism: reciprocal forepaw treading, side-to-side
head weaving, and hyperlocomotion (turning). Total
scores for each rat were calculated by summing the
individual values of each behaviour during each
5-min period.
Statistics
Microdialysate 5-HT (mean¡S.E.M.) was calculated as
fmol/30 ml, and is shown in the ﬁgures as percentages
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of basal values, averaged from four fractions collected
before treatment. Changes in dialysate 5-HT were
analysed by two-way, repeated-measures analysis of
variance (ANOVA) with time and treatment as factors,
followed by Newman–Keuls (NK) multiple com-
parison test. The individual stereotypy scores were
averaged within each treatment and analysed by one-
way ANOVA followed by NK test. Diﬀerences in the
number of c-Fos immunostained cells among the
diﬀerent treatment groups in mPFC and DR were also
tested by one-way ANOVA followed by NK test.
Statistical calculations were made using Statistica
software (StatSoft Inc., USA). Diﬀerences were con-
sidered signiﬁcant when p<0.05.
Results
Eﬀects of MK-801 and ketamine on cortical 5-HT
Two-way ANOVA showed that, with respect to
saline-injected group, the administration of MK-801
(1 mg/kg) enhanced the extracellular concentration of
5-HT to the same extent in both mPFCs (Fig. 1a) as
demonstrated by the signiﬁcant eﬀect of treatment
(F3,34=13.7, p<0.00001), time (F15,510=13.9, p<0.00001),
and treatmentrtime interaction (F45,510=4.2, p<
0.00001). Figure 1b depicts the eﬀects of uni- or bi-
lateral infusion of MK-801 on the eﬄux of 5-HT in the
mPFC. Two-way ANOVA showed that the unilateral
perfusion of MK-801 (300 mM) had no eﬀect, but bi-
lateral perfusion of MK-801 increased the extracellular
concentration of 5-HT to the same extent in both
mPFCs as demonstrated by the signiﬁcant eﬀect of
treatment (F3,30=10.8, p<0.0001), time (F15,450=11.0,
p<0.00001), and treatmentrtime interaction (F45,450=
3.4, p<0.00001). In a similar manner, two-way
ANOVA showed that, with respect to the saline-
injected group, administration of ketamine (25 mg/kg)
enhanced the extracellular concentration of 5-HT to
the same extent in both mPFCs (Fig. 2a) as demon-
strated by the signiﬁcant eﬀect of treatment (F3,18=6.4,
p<0.01), time (F15,270=10.5, p<0.00001), and treat-
mentrtime interaction (F45,270=4.1, p<0.00001).
Moreover, two-way ANOVA showed that the uni-
lateral perfusion of ketamine (3 mM) had no eﬀect, but
bilateral perfusion of ketamine increased the extra-
cellular concentration of 5-HT to the same extent in
both mPFCs (Fig. 2b) as demonstrated by the signiﬁ-
cant eﬀect of treatment (F3,22=4.1, p<0.02), time
(F15,330=3.2, p<0.0001), and treatmentrtime inter-
action (F45,330=1.5, p<0.02). There was no diﬀerence
in the level of 5-HT between both hemispheres after
bilateral application of MK-801 and ketamine.
The eﬀects of the perfusion of TTX alone and in
combination with MK-801 or ketamine are depicted in
Fig. 3. The perfusion of 1 mM TTX unilaterally in the
mPFC abolished locally the basal concentration of
5-HT without altering its concentration in the contra-
lateral mPFC (Fig. 3a), as shown by the signiﬁcant
eﬀect of treatment (F3,26=24.9, p<0.000001), time
(F15,390=11.2, p<0.000001), and treatmentrtime inter-
action (F45,390=8.2, p<0.000001). Further, the unilateral
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Fig. 1. Eﬀects of (a) systemic and (b) intra-mPFC
administration of MK-801 on dialysate serotonin (5-HT) in
the medial prefrontal cortex (mPFC). Data (mean¡S.E.M.)
are expressed as percentage changes of the four basal
pre-drug values. Number of animals is given in parentheses.
The arrow represents the systemic administration of saline
or MK-801 and the bar indicates the intra-mPFC perfusion
of MK-801. For the sake of clarity, the control groups are
depicted as dotted (........, right hemisphere) and dashed
(- - - -, left hemisphere) lines. A single injection of MK-801
(1 mg/kg i.p.) increased extracellular 5-HT in the left
[p<0.0005, Newman–Keuls (NK) test] and right (p<0.0005,
NK test) mPFC to the same extent. Unilateral perfusion of
MK-801 (300 mM) in the mPFC did not alter extracellular
5-HT ipsilaterally or contralaterally. Simultaneous perfusion
of MK-801 (300 mM) in each mPFC increased dialysate 5-HT
in the left and right mPFC (p<0.01, ipsilateral side ; p<0.005,
contralateral side, NK test).
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perfusion of 1 mM TTX in the mPFC not only abolished
the local increase in 5-HT elicited by the systemic
administration of MK-801, but also reduced signiﬁ-
cantly the eﬀect of MK-801 in the contralateral part
(Fig. 3b), as demonstrated by the signiﬁcant eﬀect of
treatment (F5,56=51.1, p<0.000001), time (F15,840=16.7,
p<0.000001), and treatmentrtime interaction (F75,840=
17.2, p<0.000001). Similar actions of TTX were ob-
served in rats given ketamine systemically (Fig. 3c).
Thus, the unilateral perfusion of 1 mM TTX in the
mPFC abolished the local increase in 5-HT elicited
by the systemic administration of ketamine in the
ipsilateral and contralateral hemispheres, as shown
by the signiﬁcant eﬀect of treatment (F5,28=22.8,
p<0.000001), time (F15,420=8.3, p<0.000001), and
treatmentrtime interaction (F75,420=7.5, p<0.000001).
Eﬀects of MK-801 on c-Fos and vGluT1
immunohistochemistry
The activation of cortical and raphe cells, measured
by c-Fos immunohistochemistry, was examined after
systemic administration of only MK-801 (1 mg/kg)
because this agent displays higher aﬃnity and selec-
tivity for the NMDA channel site (Murray et al. 2000).
One-way ANOVA showed a signiﬁcant eﬀect of group
on the number c-Fos-positive cells in the mPFC
(F2,11=105.1, p<0.0001 ; Fig. 4c) and in the DR
(F2,11=178.2, p<0.0001; Fig. 4d). Post-hoc comparisons
showed that MK-801 signiﬁcantly increased the
number of c-Fos-positive cells y10-fold in the mPFC
[p<0.01, NK test ; Fig. 4, panels (a2) and (c)] and
y8-fold in the DR [p<0.01, NK test ; Fig. 4, panels (b2)
and (d)]. The unilateral perfusion of TTX in the mPFC
reduced the number of c-Fos-positive cells in the
contralateral mPFC byy25% [p<0.01, NK test ; Fig. 4,
panels (a3) and (c)], but had no eﬀect on the DR [Fig. 4,
panels (b3) and (d)]. In double immunohistochemistry
experiments (Fig. 5), one-way ANOVA showed a sig-
niﬁcant eﬀect of group on the number c-Fos-positive
cells (F3,11=164.4, p<0.0001). The systemic adminis-
tration of MK-801 increased c-Fos labelling in vGluT1
(p<0.001, NK test) and non-vGluT1 cells (p<0.01,
NK test). In addition, the eﬀect of MK-801 on the
expression of c-Fos was greater in cells expressing
vGluT1 than in cells not expressing it (p<0.001, NK
test). In MK-801-treated rats, 82.0¡0.7% of prefrontal
cells were positive for vGluT1 and c-Fos whereas the
remaining 18.0¡0.7% were positive only for c-Fos.
Eﬀects of MK-801 and ketamine on behavioural
scores
One-way ANOVA showed a signiﬁcant eﬀect of group
on the stereotypy scores induced by MK-801 (F5,71=
153.6, p<0.0001 ; Fig. 6a) and ketamine (F5,43=155.3,
p<0.0001 ; Fig. 6b). The systemic administration
of both NMDA antagonists signiﬁcantly increased
the behavioural scores of stereotypical behaviour
(p<0.001, NK test for MK-801 ; p<0.001, NK test for
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Fig. 2. Eﬀects of (a) systemic and (b) intra-mPFC
administration of ketamine (Ket) on dialysate serotonin
(5-HT) in the medial prefrontal cortex (mPFC). Data
(mean¡S.E.M.) are expressed as percentage changes of the
four basal pre-drug values. Number of animals is given in
parentheses. The arrow represents the systemic
administration of saline or ketamine and the bar indicates
the intra-mPFC perfusion of ketamine. For the sake of clarity,
the control groups are depicted as dotted (........, right
hemisphere) and dashed (- - - -, left hemisphere) lines.
A single injection of ketamine (25 mg/kg s.c.) increased
extracellular 5-HT in the left [p<0.002, Newman–Keuls (NK)
test] and right (p<0.05, NK test) mPFC to the same extent.
Unilateral perfusion of ketamine (3 mM) in the mPFC did
not alter extracellular 5-HT ipsilaterally or contralaterally.
Simultaneous perfusion of ketamine (3 mM) in each mPFC
increased dialysate 5-HT in the left and right mPFC (p<0.05
for both hemispheres, NK test).
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ketamine). Neither unilateral nor bilateral application
of MK-801 or ketamine produced the emergence of
such behaviours. However, unilateral perfusion of
TTX in the right mPFC signiﬁcantly reduced the
behavioural scores obtained after systemic adminis-
tration of MK-801 (p<0.001, NK test) and ketamine
(p<0.001, NK test).
Discussion
Whether NMDA antagonists act preferentially within
the PFC or by inﬂuencing the activity of cortical aﬀer-
ents is not clear. Some studies have shown that intra-
thalamic (Sharp et al. 2001) or hippocampal (Jodo et al.
2005) injection of NMDA antagonists mimic the eﬀects
of systemic administration better than intra-mPFC
application, thus suggesting that, at least some of
the eﬀects, are caused by inﬂuencing the activity of
thalamic or hippocampal projections. For instance,
an activation of thalamocortical pathways may be
partly responsible for these eﬀects (Santana et al. 2011).
Systemic administration of non-competitive NMDA
antagonists also induced behavioural activation and
enhanced the eﬄux of glutamate and 5-HT in the
mPFC (Adams & Moghaddam, 2001; Lo´pez-Gil et al.
2007; Lorrain et al. 2003; Moghaddam et al. 1997),
eﬀects that were not observed following the unilateral
intra-mPFC perfusion of such drugs (Lo´pez-Gil et al.
2007; Lorrain et al. 2003). Here we observed that
systemic MK-801 evoked a sustained increase in 5-HT
that lasted more than 4 h whereas the eﬀect of
ketamine returned to baseline level within 3 h. This
pharmacokinetic diﬀerence is probably due to the
shorter half-life of ketamine. The present results sup-
port the view that the PFC is a pivotal site of action of
NMDA antagonists. Indeed, bilateral (but not uni-
lateral) perfusion of MK-801 in the mPFC elicited an
increase of cortical 5-HT eﬄux, which, in its maximal
eﬀect, was comparable to that seen after systemic
administration. The slower time-course of increase
in 5-HT with intra-mPFC application compared to
systemic administration is probably due to smaller
extracellular concentration of the drug conﬁned to a
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Fig. 3. Eﬀects of the local perfusion of tetrodotoxin (TTX,
1 mM) (a) alone, and in rats given (b) systemic MK-801 or
(c) ketamine on dialysate serotonin (5-HT) in the medial
prefrontal cortex (mPFC). Data (mean¡S.E.M.) are expressed
as percentage changes of the four basal pre-drug values.
Number of animals is given in parentheses. The arrow
represents the systemic administration of saline, MK-801 or
ketamine and the bar indicates the intra-mPFC perfusion of
TTX. For the sake of clarity, the control groups are depicted as
dotted (........, right hemisphere) and dashed (- - - -, left
hemisphere) lines. The perfusion of 1 mM TTX unilaterally
in the left mPFC abolished locally the basal concentration of
5-HT [p<0.0002, Newman–Keuls (NK) test] without altering
its concentration in the contralateral (right) mPFC. The
perfusion of 1 mM TTX unilaterally in the left mPFC abolished
not only the local increase in 5-HT elicited by the systemic
administration of MK-801 (p<0.0001, NK test) and ketamine
(p<0.0001, NK test), but also reduced signiﬁcantly the
MK-801-induced (p<0.0001, NK test) and the ketamine-
induced (p<0.0001, NK test) increase in 5-HT in the
contralateral (right) mPFC.
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limited volume of tissue. The unilateral perfusion of
TTX in mPFC diminished 5-HT eﬄux induced by
systemic MK-801 not only in the ipsilateral mPFC, but
also to great extent in the contralateral mPFC, which
conﬁrms that an important locus for these eﬀects
is in the mPFC. This is further emphasized by the
observation that ketamine experiments replicated
the MK-801 eﬀects fairly well. Overall, this suggests
that the eﬀects of systemic non-competitive NMDA
antagonists on prefrontal 5-HT, and probably the
overall state of mPFC hyperexcitability that underlies
it, require bilateral disruptions of the mPFC. However,
the question that remains, i.e. whether the bilateral
perfusion of MK-801 and ketamine produces a larger
stimulation of 5-HT cells in the DR or prefrontal
interconnectivity, is indeed crucial for this purpose. To
test the mechanism underlying our results, we applied
TTX to unilateral mPFC in the setting of systemic
NMDA receptor blockade, and measured the number
of c-Fos cells in the contralateral mPFC and the DR.
The TTX experiments here describe a marked dis-
sociation for the eﬀects on c-Fos in the contralateral
mPFC vs. the DR following systemic MK-801 admin-
istration. Furthermore, while the local infusion of TTX
almost completely attenuated the MK-801-induced
increase in 5-HT in the contralateral mPFC, the
MK-induced increase in the number of c-Fos cells was
attenuated by only about 25%. Unilateral perfusion of
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Fig. 4. Representative photomicrographs of c-Fos protein in (a1–a3) mPFC and (b1–b3) dorsal raphe nucleus (DR) following
saline (a1, b1), MK-801 (1 mg/kg) and TTX (1 mM). MK-801 increased the number of c-Fos-positive cells in (a2) mPFC and (b2) DR.
The unilateral intra-mPFC application of TTX reduced the MK-801-induced increased number of c-Fos-positive cells in (a3)
mPFC, but not in (b3) DR. Black arrows represent cells counted as positive for c-Fos whereas white arrows indicate cells
below the established threshold level of c-Fos immunostaining. Bar graphs show the quantiﬁcation of these eﬀects in
(c) mPFC and (d) DR, with total areas of 6.4 mm2 and 0.5 mm2, respectively. Values are expressed as mean¡S.E.M. of 4–6
animals per group. * p<0.01, ** p<0.001, Newman–Keuls test. Scale bar, 35 mm.
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TTX also reduced the activity of pyramidal cells
(measured as the number of cells positive for c-Fos
and vGluT1) in the contralateral mPFC. However, TTX
application did not alter the number of c-Fos-positive
cells in the DR after systemic MK-801, which disfavors
a greater activation of 5-HT neurons and supports
the idea that bilateral disruption of the mPFC is
indeed required to mimic the eﬀects of systemic
non-competitive NMDA antagonists. Although this
phenomenon appears clear cut, the underlying cel-
lular mechanisms remain to be determined. In any
event, our results can be explained by a preferential
activation of cortico-raphe projections rather than by a
direct action of these compounds on the DR. It must be
noted, however, that these eﬀects seem to apply only
to non-competitive NMDA antagonists inasmuch
as competitive antagonists increase cortical 5-HT
following unilateral exposure (Calcagno et al. 2006).
However, it is also possible that, in addition to
the competitive vs. non-competitive nature, some
compounds diﬀer also in pharmaco-distribution and
pharmaco-dynamics as well as acting at other trans-
mitter receptors. Previous work has lent support
to the view that non-competitive NMDA receptor
antagonists reduce selectively GABAergic inhibition
of pyramidal cells, thus leading to a disinhibited state
of pyramidal activity (Krystal et al. 2003; Moghaddam
et al. 1997; Olney & Farber, 1995), which is associated
with excessive neuronal activity and eﬄux of
glutamate and 5-HT within the mPFC (Adams &
Moghaddam, 2001; Lo´pez-Gil et al. 2007). The increase
of 5-HT concentration most likely results from the
elevation of the excitatory output of a subpopulation
of pyramidal neurons in layer V of mPFC that project
heavily to the DR (Gabbott et al. 2005) and tightly
control the activity of 5-HT cells (Celada et al.
2001; Hajo´s et al. 1998). Recent data (Homayoun &
Moghaddam, 2007) and the present study further
suggest that these inhibitory neurons are located
within the mPFC. In line with this assumption, it
has been shown that PCP and MK-801 reduce the
extracellular concentration of GABA in the mPFC
(Yonezawa et al. 1998). Here we show that the per-
centage of vGluT1-negative cells that express c-Fos
(18%) is coincident with the proportion of GABAergic
cells in cortical structures and thus it is tempting to
speculate that, in the conditions of the present study,
these presumed GABAergic cells are also activated
by MK-801, in line with what has been observed pre-
viously after PCP (Santana et al. 2011). This would be in
accord with tract-tracing studies showing that callosal
terminals primarily target pyramidal neurons, but
a proportion of them also synapse onto GABAergic
interneurons (Carr & Sesack, 1998).
In contrast to the changes in serotonergic trans-
mission, the mPFC itself is not suﬃcient to drive the
locomotor activation induced by NMDA antagonists
because the bilateral perfusion of MK-801 and keta-
mine did not evoke hyperlocomotion and stereotypies,
which is in accord with results showing that MK-801-
induced stereotypies are mostly independent of
mPFC integrity (Scorza et al. 2008). NMDA receptor
antagonists could also be acting within the mPFC
and the orbital cortex, thus activating corticostriatal
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Fig. 5. Representative photomicrographs of immunostaining with vGluT1 at (a)r10 and (b)r40 magniﬁcations of a section of
prefrontal cortex. As shown in panel (b), vGluT1 has a peripheral somatic distribution. Double immunohistochemistry for
vGluT1 and c-Fos protein after MK-801 administration is represented in panel (c). White arrow indicates a cell positive for
c-Fos and black arrows designate cells immunopositive for vGluT1 and c-Fos ; one of such cells can be seen in the centre of
the inset in panel (c) at higher magniﬁcation. Bar graph in panel (d) shows the quantiﬁcation of the eﬀects of MK-801 on
vGluT1 and c-Fos in the mPFC. Values are expressed as mean¡S.E.M. of three animals per group. * p<0.01, ** p<0.001,
Newman–Keuls test. Scale bars : (a)140 mm; (b, c) 35 mm.
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pathways (West & Grace, 2002) and inducing an in-
crease in horizontal locomotion. However, previous
ﬁndings indicate that these behaviours are somewhat
accounted for by a direct action of NMDA antagonists
on caudate putamen and nucleus accumbens (Burns
et al. 1994; De Leonibus et al. 2001; Kelley et al. 1986;
McCullough & Salamone, 1992; Mogenson et al. 1980).
It is of note that these eﬀects were observed only when
NMDA antagonists were administered bilaterally,
thus indicating that, in line with our observations,
both hemispheres must be aﬀected for the emergence
of these behaviours. In this regard, it is also important
to mention that hippocampal-accumbal projections
may play a role in mediating the increase in locomotor
activity elicited by NMDA receptor antagonists (Jodo
et al. 2005). In the present work, however, unilateral
perfusion of TTX in the mPFC reduced stereotypy
scores induced by systemic MK-801 and ketamine.
Interestingly, these changes occur in parallel with
those of pyramidal activity (measured as c-Fos pro-
duction in vGluT1-positive cells) and 5-HT eﬄux,
which is in line with the ﬁnding that the stereotypies
elicited by certain doses of MK-801 correlate with
pyramidal cell ﬁring in the PFC (Jackson et al.
2004). Also in line with these eﬀects, Takahata &
Moghaddam (2003) found that application of an
AMPA receptor antagonist in the mPFC abolished
locomotor activity and stereotypy elicited by systemic
PCP. Therefore, although the hyperlocomotion and
stereotypies observed do not seem to originate in the
mPFC, this brain region appears to mediate the ability
to reduce the emergence of these behaviours. Bilateral
prefrontal projections to dorsal and ventral striatum
(Gabbott et al. 2005; Sesack et al. 1989) are probably
responsible for the behavioural contributions of these
interconnected structures.
In summary, the results of this study support the
view that an abnormal communication between both
prefrontal cortices would lead to a state of cortical
hyperactivity measured as increased 5-HT eﬄux and
c-Fos expression. However, a clear dissociation has
been found between these neurohistological changes
in PFC and behavioural stereotypies, which did
not appear to be generated as a consequence of
mPFC function. Therefore, it would appear that
the circuitry governing the increases in extracellular
5-HT, c-Fos and stereotypical behaviour are diﬀerent
when examining eﬀects of systemic vs. uni- or bilateral
non-competitive NMDA antagonists together with
the inﬂuence of unilateral TTX. Blockade of non-
competitive NMDA receptor antagonist-induced
increases in locomotor activity is a key ﬁnding used
throughout the pharmaceutical industry in supporting
novel antipsychotic drug development. Thus, a better
knowledge of the somewhat separate but partially
overlapping circuits involved in mediating the various
behavioural and neurochemical eﬀects of NMDA
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Fig. 6. Eﬀects of systemic and local (unilateral or bilateral)
administration of MK-801 and ketamine (Ket) on stereotypy
scores. (a) Systemic administration of MK-801 (1 mg/kg i.p.)
was the only treatment that signiﬁcantly increased
stereotypies (turning, forepaw treading, head weaving) in
rats. This increase was reduced by the unilateral perfusion of
1 mM TTX. (b) Systemic administration of Ket (25 mg/kg s.c.)
was the only treatment that signiﬁcantly increased
stereotypies in rats. This increase was reduced by the
unilateral perfusion of 1 mM TTX. Behavioural scores are
expressed as mean¡S.E.M. * p<0.001, Newman–Keuls test.
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receptor antagonists would be likely to increase the
predictive utility of this model. In this regard, putative
antipsychotic drugs should be able to block the
multiple eﬀects of this class of psychotomimetic drugs.
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